Why did Roche's immunotherapy fail?

An experimental cancer treatment from Roche failed to improve survival in a major lung cancer study, the company said Tuesday

November 26, 2024 Check out STAT+

Sponsored By

Sebastien Bozon/AFP via Getty Images STAT+ | Roche immunotherapy fails in lung cancer study, raising questions about drug's target The company said that it was awaiting results from other trials of the drug, tiragolumab, but that it continuously reviews its programs. By Andrew Joseph STAT+ | UnitedHealth pays its own physician groups considerably more than others, driving up consumer costs and its profits By paying its doctor practices higher rates, UnitedHealth Group can capture higher profits while driving up costs for consumers By Bob Herman, Casey Ross, Lizzy Lawrence, and Tara Bannow STAT+ | Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases With the Arrowhead collaboration, Sarepta is buying into a lucrative, fast-moving race to develop RNA drugs for other rare diseases. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser